<DOC>
	<DOCNO>NCT01052142</DOCNO>
	<brief_summary>The purpose study determine whether Lipovaxin-MM , new anti-cancer vaccine , safe effective improve body 's ability destroy cancer cell patient metastatic melanoma .</brief_summary>
	<brief_title>Safety Study Liposomal Vaccine Treat Malignant Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Key Patients incurable stage IV malignant melanoma standard curative therapy exist OR patient locoregionally recurrent melanoma ( include local metastasis , transit metastasis satellitosis ) surgery best therapeutic option . Must able willing provide write informed consent . Eastern Cooperative Oncology Group Performance Status 0 1 . Life expectancy ≥12 week . Female subject must nonchildbearing potential use appropriate contraception . Positive test cell mediate immunity . Key Brain metastases spinal cord compression , unless treatment complete least 4 week entry stable without steroid treatment least 4 week . Previous immunotherapy ( except IL2 interferonbased therapy ) melanoma . Inadequate bone marrow reserve . Serum bilirubin ≥1.2 time upper limit normal . In absence metastasis , liver transaminase level great 1.5 time upper limit normal . If metastasis evident , liver transaminase level 2.5 time upper limit normal acceptable . Inadequate renal function . Evidence severe uncontrolled systemic disease . Unresolved toxicity ≥CTC Grade 2 previous anticancer therapy except alopecia ( applicable ) unless agree patient enter discussion Medical Monitor . Participation trial investigational agent within prior 30 day . HIV infection . Immunosuppressive therapy include corticosteroid within 4 week screen . Pregnant breastfeeding female .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Melanoma</keyword>
	<keyword>Cancer vaccine</keyword>
</DOC>